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ABSTRACT 
Detection of mycotoxin biomarkers in urine of humans and animals provides a direct 
approach for assessing exposure to these mycotoxins as opposed to the indirect approach of 
food analysis, which in most cases is affected by the heterogeneity of the toxin in the food 
samples. Seven (7) mycotoxins and their metabolites (total 18 analytes) were selected and an 
LC-MS/MS method for their determination in human urine was developed and validated. The 
method consisted of direct analysis of two mycotoxin conjugates, deoxynivalenol-glucuronide 
and zearalenone-glucuronide without beta glucuronidase digestion of the urine samples. Since 
high method sensitivity is of utmost importance in such study, critical factors which could 
improve the analyte recovery and method sensitivity were investigated by a D-optimal 
experimental design. Urine samples (10 mL) were first extracted with 15 mL ethyl 
acetate/formic acid (99/1, v/v) followed by SAX SPE clean-up of the acidified aqueous 
fraction. Both extracts were combined and analyzed using an LC-MS/MS system operated in 
the positive ionization mode. A total run time of 28 minutes was adopted with all the 18 
analytes eluting within 15 minutes. 
The method was validated by taking into consideration the guidelines specified in 
Commission Decision 2002/657/EC and 401/2006/EC. Forty samples obtained from 
volunteers within the laboratory research group were analyzed as part of a pilot study. All 
results were expressed per mg creatinine. A total of 9 samples were found contaminated with 
one or more of the following analytes; DON, OTA, OTα, 4-OH OTA, ZEN, CIT and β-ZOL. 
One-eighth (5/40) of the samples were contaminated with DON in the range of 3.7-67 ng mg-
1
 creatinine. Samples with detectable levels of DON did not show any co-occurrence of DON-
3Glu. One sample was found to be contaminated with 4-OH OTA (<LOQ), co-occurring with 
only OTA (0.2 ng mg
-1
 creatinine). OTα (up to 4.4 ng mg-1 creatinine) was detected in three 
other samples co-occurring with low levels of OTA (up to 0.3 ng mg
-1
 creatinine) and no 4-
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OH OTA detected. ZEN was detected in 10% (4/40) of the samples analyzed. Three samples 
were contaminated with β-ZOL (3.3-20 ng mg-1 creatinine), co-occurring with ZEN (<LOQ-
10.8 ng mg
-1
 creatinine). The ratio of ZEN/β-ZOL varied for all the three samples. α-ZOL was 
not detected in any of the 40 samples. CIT was detected in one sample at 4.5 ng mg
-1
 
creatinine. This is the first study carried out with a small group of the Belgian population to 
assess exposure to mycotoxins using biomakers. 
Keywords: Mycotoxin, biomarkers, urine, glucuronide, experimental design, stability study 
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1. INTRODUCTION 
The classical approach for exposure assessment to mycotoxins has, for the past decades been 
based on detecting and quantifying the presence of this contaminant in foods. This approach is 
thought not to be reliable because it is flawed by inherent variability in (i) food contamination 
levels (ii) cooking (iii) individual consumption and individual toxicokinetics and 
toxicodynamics. On the other hand, detecting the presence of mycotoxin biomarkers in 
biological fluids such as blood and urine could be more useful and reliable in short-term and 
long-term exposure assessment as well to be able to predict future adverse health 
consequences. Deoxynivalenol (DON), aflatoxin B1 (AFB1), ochratoxin A (OTA), fumonisin 
B1 (FB1), T2 toxin and zearalenone (ZEN) are the most common mycotoxins which 
contaminate food and feedstuffs around the world. A thorough review on the metabolic 
pathway of the different mycotoxins in animals and humans and their possible transfer in 
urine has revealed a quite complex with sometimes conflicting outcomes for some analytes. 
Thus, for the purpose of this work, a review on the toxicokinetics and metabolism of each of 
these toxins would provide clues on the most frequently occurring metabolites in human urine 
which might be useful for exposure assessment. 
DON and its detoxification metabolite DON-3-glucuronide (DON-3Glu) has often been 
reported in the urine of exposed humans. In a study carried out in the United Kingdom by 
Turner et al. [1] a strong correlation was found between these urinary metabolites (the sum of 
the free DON and DON-3Glu) and cereal intake of the study population. Still in a related 
study performed by the same group of authors, the mean transfer of DON to urine was 
estimated to be 72% [2]. For these reasons, detecting and or quantifying the sum of these 
metabolites (DON and DON-3-glucuronide) in human urine has been recommended for 
biomonitoring of this toxin  
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The increase in the sphinganine (Sa) to sphingosine (So) (Sa/So) ratio in urine and serum was 
proposed as a functional biomarker to evaluate exposure to FB1 in exposed animals [3]. When 
this biomarker was investigated in serum and urine in several human studies, it resulted in 
inconclusive outcomes [4-7]. FB1 does not appear to undergo any major metabolism as 
incubation with primary rat hepatocyte cultures and subcellular enzyme fractions failed to 
produce detectable metabolites [8]. Furthermore, FB1 was recovered unaltered in the urine 
faeces and bile of dosed animals. For these reasons, recent studies have recommended the use 
of the parent analyte (FB1) as an alternative biomarker [9]. Hydrolysis of the two tricarballylic 
acid ester groups of FB1 has been reported to occur in the gut of vervet monkeys [10-11] and 
could possibly serve as an alternative biomarker. However, hydrolysis of FB1 has not yet 
been reported with human cell culture studies. 
Biomarkers of exposure to OTA have been thoroughly investigated and documented in many 
scientific publications. Gilbert et al. [12], found a positive correlation between the urinary 
concentration of OTA and the consumption of OTA, while Munoz et al. [13] reported the 
presence of OTA and its major metabolite ochratoxin alpha (OTα) in 100% of the samples 
analyzed. OTα which is produced from the hydrolysis of OTA by the gut microflora in the 
intestine was the major metabolite detected in the urine of rats [14]. The hydroxylated form of 
OTA (4-OH OTA) was detected in urine of 96% of children under 5 years old in Sierra Leone 
at concentrations of 0.04-21 ng/mL [15]. Data on the formation of genotoxic products of OTA 
still remain inconclusive as in vivo experiments conducted with male Fischer-344 rats treated 
orally with high levels (1-2 mg/kg bodyweight) of 
3
[H]OTA did not reveal significant 
detectable levels of OTA-DNA adduct [16-17]. 
 
ZEN, a mycoestrogen which is a frequent contaminant of cereals and especially breakfast 
cereals, was suspected to be a triggering factor for central precocious puberty observed in 
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adolescent females in the United States [18]. Review on the toxicity, occurrence, metabolism 
and detoxification of ZEN suggested two major biotransformation pathways in animals: (1) 
hydroxylation resulting in the formation of alpha zearalenol (α-ZOL) and beta zearalenol (β-
ZOL) assumed to be catalyzed by 3α and 3β hydroxyl steroid dehydrogenase respectively and 
(2) conjugation of ZEN and its reduced metabolites with glucuronic acid [19]. Till date, no 
paper has reported the presence of α-ZOL-glucuronide and β-ZOL-glucuronide in human 
urine samples.  
Human exposure to aflatoxins (AFs) is a concern worldwide because AFs are potent cancer-
promoting agents, especially liver cancer (International Agency for Research on Cancer 
(IARC), 1993) [20]. Animal studies have shown that under normal conditions, 50% of the 
orally administered dose of AFB1 is quickly absorbed from the duodenal region of the small 
intestine and enters the liver through the hepatic portal blood supply, where it is metabolized 
in several derivatives [21]. The metabolites of AFB1 detected in human urine include aflatoxin 
P1 (AFP1), aflatoxin Q1 (AFQ1), aflatoxin M1 (AFM1) and DNA-adduct (AFB1-N7Guanine). 
The excretion rate of the different aflatoxin metabolites in human urine is not clearly defined. 
However, in vitro studies using primate and human liver microsomes have demonstrated that 
AFQ1 is a major AFB1 metabolite, with AFM1, the hydroxylated metabolite constituting less 
than 10% of the total metabolized AFB1 [22-23]. Accordingly, in a study carried out in China, 
the levels of urinary AFQ1 were 60 fold higher than those of AFM1. Levels of AFQ1 were 
strongly correlated (r = 0.673) with detected levels of AFB1-N7Guanine adduct (AFB1-
N7Gua), a strong biomarker for cancer effect. Consequently, AFQ1 was suggested as a 
predictive marker for AFB1 exposure [24]. However, the use of this metabolite is strongly 
compromised due to the lack of commercial standards.  
Several acute and chronic toxic effects were observed in humans after consumption of food 
contaminated with T-2 toxin. T-2 toxin is rapidly metabolized by esterases, resulting in 
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several metabolites being detected in vivo and in vitro after ingestion. The spectrum and the 
ratios of T-2 metabolites in animals strongly depend on the investigated species [25]. The 
main biotransformation pathway is deacetylation of the C-4 acetyl group which leads to HT-2 
toxin. In cell culture studies with human fibroblast cells and isolated microsomes from liver, 
kidney and spleen of various animals, HT-2 toxin was detected as the sole metabolite of T-2 
toxin [26-29]. Other metabolites detected after incubation of T2 toxin with the Chinese 
hamster ovary cells and the African green monkey kidney cells included traces of T-2 triol 
and T-2 tetraol [27]. Johnson et al. [30] reported a possible metabolism of T-2 toxin to 
neosolaniol by carboxylesterase activity in human blood cells. In these cells, both metabolites 
(HT2 and neosolaniol) were produced in equal amounts. 
 
Citrinin (CIT), a nephrotoxin, has been implicated in several disease outbreaks in animals and 
humans (IARC, 1986) [31]. Literature on the toxicokinetics and metabolism of CIT in humans 
is very scarce. However, Dunn et al. [32] isolated and successfully identified dihydrocitrone 
as the main urinary metabolite of CIT in rats. Low levels (2-5 ng/mL) of the un-metabolized 
toxin were also detected in the urine of humans [33], indicating a possible but low level of 
excretion. However, the analytical challenges associated with the detection of this analyte in 
biological and food matrices usually make this analyte escape routine surveillance. 
 
Only a few analytical methods for multi-determination of mycotoxin biomarkers in human 
urine have been reported so far [34-36]. Most often, only a limited number of analytes are 
targeted due to the unavailability of commercial standards, which otherwise can be 
synthesized at the laboratory scale. Example of such analytes include the glucuronides DON-
3GLu and ZEN-4Glu. Analysis has thus been based on detecting the presence of the parent 
analyte after β-glucuronidase digestion. Warth et al. [37] focused on the direct determination 
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of one of the conjugated forms (mycotoxin glucuronide, i.e (DON-3-Glu)) without β-
glucuronidase digestion. This is the only direct assessment approach  reported so far. No other 
analytes except DON were included in the method reported by Warth et al. [37]. 
 
In this study, a sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) 
method for the simultaneous determination of DON, OTA, FB1, AFB1, ZEN, T-2 and CIT as 
well as their main metabolites in human urine was developed and validated. Direct 
determination of the conjugated forms namely DON-3Glu ZEN-4Glu without enzyme 
digestion of the urine samples was performed. Critical factors which could have an influence 
or effect on the analyte recovery and method sensitivity were investigated by a D-optimal 
experimental design. The optimized analytical protocol was used to analyze samples obtained 
from volunteers within the laboratory research group. Furthermore, the short term and long 
term stability of the different mycotoxin biomarkers spiked in urine sample was investigated 
as no literature was available at the time this work was been carried out. 
 
2. MATERIALS AND METHODS 
 
2.1 Reagents and Materials 
 
LC-MS grade methanol, HPLC grade methanol and n-hexane were purchased from VWR 
International (Zaventem, Belgium). Dichloromethane and ethyl acetate were purchased from 
Acros Organics (Geel, Belgium). Ammonium acetate was supplied by Grauwmeer (Leuven, 
Belgium). Ammonium formate, picric acid (1.3%) and creatinine (Crea) standard were 
supplied by Sigma-Aldrich (Bornem, Belgium). Chloroform, methyl-ter-butyl ether, acetic 
acid, formic acid (FAc), hydrochloric acid (HCl) 37%, sodium hydroxide and sodium 
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carbonate (Na2CO3) were supplied by Merck (Darmstadt, Germany). Bond Elut strong anion 
exchange (SAX) SPE cartridges were obtained from Varian (Sint-Katelijne Waver, Belgium). 
Oasis HLB SPE cartridges were obtained from Waters (Zellik, Belgium). Ultrafree-MC 
centrifugal filter devices (0.22 μm) of Millipore (Millipore, Brussels, Belgium) were used. 
Trifluoroacetic acid (TFA) was obtained from Fluka (Buch, Switzerland). Water was purified 
on a Milli-Q Plus apparatus (Millipore, Brussels, Belgium).  
 
2.1.1 Standards 
Mycotoxin-reference standards and metabolites namely AFB1, HT-2 toxin, OTA, ZEN, FB1, 
deepoxy-deoxynivalenol (DOM), CIT, α-ZOL and β-ZOL, were purchased from Sigma-
Aldrich (Bornem, Belgium). T-2 toxin was purchased from Biopure (Tulln, Austria). DON 
and AFM1 were purchased from Fermentek (Jerusalem, Israel). OT was obtained from 
Coring System Diagnostix (Gernsheim, Germany). Stock solutions of DON, AFM1, AFB1, 
HT-2 toxin, T-2 toxin, OTA, ZEN, FB1, CIT, α-ZOL and β-ZOL were prepared in methanol at 
a concentration of 1 mg/mL.  DOM and OT were obtained as solutions, 100 μg/mL and 10.3 
μg/mL respectively in acetonitrile. DON-3Glu was synthesized using the protocol described 
by Wu et al. [38] while AFB1-N7Gua was prepared using the procedure described in Egner et 
al. [39]. Hydrolyzed FB1 (HFB1 or aminopentol) was synthesized by alkaline hydrolysis as 
described in Pagliuca et al. [40]. All stock solutions were stored at -20 °C. From the 
individual stock solutions, a standard mixture was prepared at the following concentrations: 
DON, DOM, β-ZOL, CIT and ZEN (5 ng/μL);, FB1 and T-2 toxin (0.2 ng/μL); α-ZOL and 
AFB1 (2 ng/μL); OTα and OTA (0.1 ng/μL); DON-3Glu (5 ng/μL); AFM1, (0.05 ng/μL); 4-
OH OTA, HT-2 toxin, HFB1 and AFB1-N7Gua (1 ng/μL). The standard mixture was prepared 
in methanol, stored at -20°C and renewed every 2 weeks.  
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2.2 Samples 
Colleagues within the laboratory research group were kindly requested to provide urine 
samples including own samples. Samples from friends and family members of these 
colleagues were also welcomed. A written and approved informed consent was obtained from 
all the volunteers. The informed consent was in accordance with the Helsinki declaration on 
ethical principles for medical research involving human subjects. Since it is the most 
concentrated, first morning urine was obtained from each participating individual in urine 
recipients and stored at −20°C until analysis. In total 40 samples were collected. The 
participants were not subjected to any diet restriction before and during the sampling period 
and as such there were no inconveniences or health risk involved. Furthermore, all 
participants were asked to be anonymous but were required to indicate their sex M for male, F 
for female, C for children and or combinations of these. All samples were frozen within 6 hrs 
after collection. After confirmation with external standards, samples (other than the 40 
samples collected) with undetectable levels of the target analytes were used for spiking and 
recovery studies. 
 
2.3 Sample Preparation 
 
Two sample preparation protocols were optimized with the aim of (1) obtaining satisfactory 
recoveries for the different analytes investigated and (2) eliminating as much matrix 
interferences as possible and hence reaching the low detection limits required for this study. 
The two protocols consisted of (1) liquid-liquid extraction (LLE) with ethyl acetate/FAc 
(99/1, v/v) followed by SAX-SPE clean-up and (2) using Oasis HLB SPE cartridges. Each of 
these sample preparation protocol had its strengths and weaknesses. Both approaches are 
described below. 
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2.3.1 LLE procedure 
 
2.3.1.1 Experimental design for the optimization of the LLE procedure 
 
The LLE procedure was optimized using a D-optimal design with star points. The 
experimental design consisted of 37 runs and was performed in one randomized batch. The 
response (analyte peak area) for each run was used to compute the statistical analysis. Five 
factors (one qualitative factor and four quantitative factors) with three levels each were 
considered for the experimental design. The factors included (1) extraction solvent (two polar 
aprotic solvents (ethyl acetate and methyl ter-butyl ether) and one non-polar aprotic solvent 
(chloroform)) with (2) varying percentages of FA (0.1%, 1.55% and 3%, v/v), (3) volume of 
extraction solvent (10 mL, 20 mL and 30 mL), (4) extraction time (10 min, 20 min and 30 
mins) and (5) evaporation temperature (40°C, 50°C and 60°C). The statistical relationship 
between a response Y and the experimental variables Xi, Xj is of the following form: Y = β0 
+βiXi +βjXj +βijXiXj +βiiX
2
i+βjjX
2
j+. . . ε, where the βs are the regression coefficients and ε is 
the overall experimental error. The linear coefficients βi and βj describe the quantitative effect 
of the respective variables. The cross coefficient βij measures the interaction effect between 
the variables and the square terms βiiX
2
i and βjjX
2
j describe the nonlinear effects on the 
response.  
 
2.3.1.2 Sample clean-up using LLE in combination with SAX SPE clean-up 
 
The optimum conditions obtained from the experimental design described above were 
applied. Prior to the start of analysis, all urine samples were centrifuged at 4000g for 10 mins 
to sediment particulate matter. Samples with undetected levels of the mycotoxin biomarkers 
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were used for spiking experiments. A 10 mL portion of the centrifuged urine was then used 
for analysis. To the urine samples, 15 mL of extraction solvent ethyl acetate/FAc (99:1, v/v) 
were added followed by extraction on an orbital shaker for 30 mins. Centrifugation was later 
performed at 4000g for 10 mins. The ethyl acetate phase was aspirated into a new extraction 
tube and dried at 40°C under a gentle stream of nitrogen. The pH of the aqueous phase 
(acidified urine) was adjusted to pH between 6.5-7 with Na2CO3 (0.4 M). The pH-adjusted 
urine was diluted (1/5, v/v) in methanol and loaded on a pre-conditioned SAX SPE cartridge 
for sample clean-up. The SAX SPE cartridge was conditioned by passing 10 mL of 
methanol/water (85/15, v/v) followed by 10 mL of methanol. The loaded sample was allowed 
to flow-through at a flow rate of one drop per second. The SAX SPE cartridge was then 
washed with 1 mL water. The analytes were eluted with 5mL of acidified methanol (1% FAc). 
The eluate from the SAX SPE cartridge was combined with the residue obtained after LLE 
with ethyl acetate. The pooled extract was evaporated at 40°C. The residue of the combined 
fractions was reconstituted in 200 µL of injection solvent which consisted of 
water/methanol/FAc (61.8/37.9/0.3, v/v/v). Hexane (500 µL) was added and vortexed for 1 
min. The content was brought into a centrifugal filter (Millipore corporation, Billerica, United 
States) and centrifuged for 15 mins at 14000g. A 150 µL aliquot of the aqueous phase was 
transferred into a vial for LC-MS/MS analysis. Figure 1 shows a schematic representation of 
the sample preparation protocol. 
 
2.3.2 Sample clean-up using Oasis HLB cartridges 
 
The SPE protocol consisted of diluting 10 mL urine sample with ultrapure water (1/1, v/v) 
followed by loading of the diluted urine on a pre-conditioned Oasis HLB cartridge. The 
cartridge was conditioned with 10 mL of dichloromethane/methanol (70/30, v/v) containing 
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50 mM HCl followed by 5 mL methanol. Acidified water (50 mM HCl), 20 mL, was used to 
activate the functional hydrophilic groups. The cartridges were then rinsed with 10 mL water. 
Samples were loaded and allowed to flow through at a flow rate of one drop per second. 
Interfering substances were washed off with 2 mL water without letting the cartridges go dry. 
Elution was performed with 10 mL dichloromethane/methanol (70/30, v/v) containing 50 mM 
HCl. The eluate consisted of two phases, a colored upper phase (which consisted of residual 
water after the washing step) and a transparent colorless lower phase 
(dichloromethane/methanol phase). The colored upper phase was aspirated separately into a 
clean test tube to which 5 mL of ethyl acetate/TFA (99/1, v/v) was added. The mixture was 
vortexed and centrifuged for 3000g for 3 mins. The ethyl acetate/TFA (99/1, v/v) phase was 
carefully aspirated and combined with the dichloromethane/methanol extract. This combined 
solution was then evaporated to dryness at 40°C. The final residue was re-dissolved in 200 µL 
of the injection solvent. 
 
2.4 Synthesis, purification and characterization of DON-3-glucuronide, AFB1-N7Gua 
adduct and HFB1 
 
As previously mentioned, DON-3Glu and AFB1-N7Gua were synthesized using the protocol 
described in Wu et al. [38] and Egner et al. [39] respectively. Hydrolyzed FB1 (HFB1 or 
aminopentol) was synthesized by alkaline hydrolysis as described in Pagliuca et al. [40]. 
Slight modification in the synthetic protocols for DON-3Glu and AFB1-N7Gua led to 
significant increases in the overall yields when compared to the original approaches described 
in the literature. These modifications are not described in this paper. Purification of the 
synthesized compounds DON-3Glu, AFB1-N7Gua and HFB1 was carried out on a Waters 
HPLC instrument coupled to a Waters Fraction Collector III (Waters, Zellik, Belgium). 
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Characterization of the synthesized compounds was performed by performing accurate mass 
measurements using an Exactive Orbitrap Mass Spectrometry (Thermo Scientific, Rockwood, 
USA). Quantification was carried out by spectrophotometric measurements as described in 
the original protocols. The synthesized metabolites were used for validation studies and for 
authentication of suspected peaks.  
 
2.5 Chromatographic Conditions  
 
The analytical column used was a 100 mm x 2.1 mm i.d., 3.5 μm, ZORBAX SB-C18, 
connected to a 10 mm x 2.1 mm i.d., 5 μm, ZORBAX Eclipse XDB-C8 guard column 
(Agilent, Diegem, Belgium). Two solvent mixtures were used as mobile phases, both 
containing 5mM ammonium formate. Solvent A consisted of water/FAc (99.7/0.3, v/v) while 
methanol/water/FAc (94.7/5/0.3,v/v/v) was used as solvent B. The sample injection volume 
was 20 μL. A solvent gradient (flow rate of 0.25 mL/min) was adopted for a total run time of 
28 min, with all the 18 analytes eluting over 4-15 mins while the last 13 mins were used for 
column cleaning and regeneration. The solvent gradient was as follows: 0-1 min, 90% A; 1-5 
min, 90-50% A, 5-10 min, 50-35% A; 10-15 min, 35-20% A; 15-25 min, 20-90% A; 25-28 
min, 90% A. 
 
2.6 Mass Spectrometry Conditions 
 
Detection and quantification were performed with a Waters Acquity UPLC apparatus coupled 
to a Micromass Quattro Micro triple quadruple spectrometer (Waters, Milford, MA, USA). To 
obtain optimum sensitivity and selectivity, the mass spectrometer analyses were carried out 
using multiple reaction monitoring (MRM) mode. Ionization was performed in the positive 
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electrospray ionization (ESI) mode. The following instrumental settings were applied: source 
and desolvation temperatures 130°C and 350°C, respectively; capillary voltage 3.2 kV; cone 
and desolvation gas flows of 20 and 800 Lh
-
1, respectively. Other instrumental parameters 
such as cone voltage and collision energy were optimized by direct infusion of 20 ng/μL 
freshly prepared standard solutions in methanol/ultrapure water (50/49.7, v/v) containing 
5mM ammonium formate and 0.3% FAc at a flow rate of 10 µL/min for 0.5 min. The 
precursor ion for each analyte was mass-selected by the first quadruple and fragmented 
through a combination of cone voltages and collision energies to obtain the product ion of 
each analyte. Two product ion transitions for each analyte were selected in the final method 
and their collision energies further optimized. The primary product ion (first transition), 
which corresponds to the most abundant product ion, was used for quantification while the 
secondary product ion (second transition) was used for confirmation. The MS parameters for 
each analyte are shown in Table 1. 
 
2.7 Method Validation.  
 
Commission Decision 2002/657/EC [41] and 401/2006/EC [42]were used as guidelines for 
the validation studies. The intra-laboratory validation parameters consisted of limit of 
detection (LOD), limit of quantification (LOQ), apparent recovery, precision, 
selectivity/specificity and linearity. Each of the above-mentioned parameters was determined 
using blank urine samples. The apparent recovery (assessed by estimating the bias) and 
linearity (evaluated through the lack of fit test) were determined using one experimental 
design as follows. Six sets of samples were used. Five-point calibration curves were 
constructed in matrix-matched samples. The calibration range for each analyte is shown in 
Table 2. A blank sample (in triplicate) fortified with standards to 10 ng/mL for each analyte 
17 
 
was used to estimate the method bias (apparent recovery). A non-spiked blank sample always 
constituted one of the five points of the calibration curve. Analysis of each concentration level 
was performed in triplicate. The peak area of each analyte was plotted as a function of the 
spiked analyte concentration. From the established calibration curve, a lack of fit test was 
performed to assess the adequacy of the linear model in addition to the commonly reported 
regression coefficients (R2). LOD and LOQ were determined by serial dilution of spiked 
urine samples. They were also evaluated by using the signal-to-noise (S/N) ratio, which have 
been defined and set as 3:1 and 10:1 respectively by the International Union of Pure and 
Applied Chemistry (IUPAC) [43].  
The precision of the analytical method was evaluated by injecting (3 times) the analytes 
spiked in blank urine samples at concentrations of 5 ng/mL and 10 ng/mL and determining the 
relative standard deviation (RSD) of the peak areas. Both intra-day RSD (RSDr) and inter-day 
RSD (RSDR) (resulting from three consecutive days of analysis) were computed.  
 
2.8 Matrix effect and stability studies 
 
2.8.1 Matrix effect 
 
The influence of matrix components on the MS/MS signal can vary from sample to sample 
due to inter-individual variability in the urine samples. However, to have an idea on the 
possible matrix influence, the first morning void blank urine of 5 randomly selected 
individuals, 3 males and 2 females was separately evaluated. For each sample a five point 
calibration curve was constructed (calibration range, same as those used to determine the 
method linearity). The ratio of the slope obtained with fortified blank samples cleaned-up 
prior to the spiking to the slope of a calibration curve established in pure solvent, was 
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computed and expressed as a percentage of the signal recovered. Each concentration level was 
carried out in triplicate. 
 
2.8.2 Stability studies 
 
To have an insight into the stability of the different mycotoxins and their respective 
metabolites, a short term and long term stability study design was applied. For the short term 
stability test, 2 batches, each consisting of five sets of samples were used. A batch represented 
the specific storage temperature at which the samples were stored (4°C and 25°C for batch 1 
and 2 respectively). Each of the five sample sets within each batch represented a specific 
storage period: 3 hrs, 6 hrs, 1 day, 3 days and 5 days. For each sample set, two series of 
analysis were performed concurrently: a begin spike and an end spike experiment. The 
experimental protocol was as follows. For the begin spike, samples were spiked to 10 ng/mL 
for each analyte (in five replicates) and kept at 4°C or 25°C for 3 hrs, 6 hrs, 1 day, 3 days and 
5 days prior to analysis. To compensate for matrix variation during storage, another set of the 
same sample (end spike) was kept under the same storage temperature as the begin spike but 
was left un-spiked at time zero (T=0). After the desired storage period, the end spike samples 
were used to construct a five-point calibration curve. The ratio of the calculated recovered 
concentration (obtained from extrapolating with the calibration curve) to the theoretical 
spiked concentration was used to determine the percentage of the analyte degraded under the 
different treatment (time, temperature) conditions. For the long term stability, the protocol 
was the same like with the short term stability studies except for the fact that the storage 
temperature of the samples was -21°C for a period of two months.  
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2.9 Creatinine analysis 
 
An in-house spectrophotometric method based on the principle of Jaffe’s reaction was 
optimized for the determination of Crea in urine samples. In summary, 18 mM picric acid was 
reacted with 85 mM NaOH to form alkaline picrate. This solution was stored in the dark in an 
amber glass recipient. Alkaline picrate (2mL) was reacted with 1 mL of diluted urine (1/100, 
(v/v) in ultrapure water). The optical density was measured at 495 nm after 25 mins using a 
Philips PU 8620 spectrophotometer. Samples with a Crea concentration below 1.3 µg/mL 
(detection limit) were not to be considered for biomarker analysis.  
 
3. RESULTS AND DISCUSSION 
 
High method sensitivity is of utmost importance since the concentration of these analytes in 
urine samples is most often present in the low ng/mL range. 
 
3.1 Sample preparation: preliminary investigations 
 
The two SPE clean-up protocols developed in this work were compared with each other and 
then to two other so called “fast” sample preparation approaches such as (1) dilute, evaporate 
and shoot and (2) dilute and shoot. The latter approach gave very low signal intensity (high 
LOD, > 10ng/mL) for most of the analytes. Considering that these biomarkers are present in 
very low concentrations (low ng/mL) in urine samples, such a less sensitive approach was 
considered not suitable for routine monitoring of mycotoxin biomarkers. The most probable 
reason for this low sensitivity could be attributed to the relatively low sensitivity of the triple 
quadruple MS used in this work. Moreover, this approach might not be considered suitable 
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because it could lead to a shortened lifespan of the analytical column, due to increased 
deposition of matrix components on the analytical column. The second approach, dilute, 
evaporate and shoot was tested as follows. A 10 mL portion of urine was diluted with 
methanol (1/1, v/v) from which 10 mL was taken and evaporated at 50°C. Though this 
approach was practically very easy to execute, it resulted in a thick sedimentation after drying 
which could dissolve completely only in 1 mL of injection solvent. This resulted in very high 
analyte LODs. Furthermore, significant signal enhancement (SSE) was observed for ZEN 
(average of 50%) and FB1 (average of 130%). This enhancement was inconsistent as it varied 
from sample to sample and between days. Because of the above mentioned reasons, this 
approach was not considered suitable and hence an alternative sample clean-up involving an 
SPE procedure was deemed necessary. 
 
3.2 Comparison of SAX SPE and Oasis HLB SPE clean-up approaches 
 
From the practical point of view, the procedure for sample clean-up with Oasis HLB cartridge 
was less labor-intensive than sample clean-up with SAX SPE cartridges. However, as 
previously mentioned in section 2.3.2, the eluate after SPE with Oasis HLB cartridges was 
subjected to further treatment (clean-up). The eluate consisted of two phases. Meanwhile, 
analysis of the complete eluate without further sample clean-up led to significant signal 
suppression for all the different analytes. Most of the matrix components were present in the 
upper phase of this eluate which could be seen visually through the intense coloration of this 
fraction. However, this upper phase (most probably a water phase) could not be discarded as it 
contained FB1. FB1 is more water soluble than in mixtures of dichloromethane and methanol. 
The colored upper phase was aspirated separately into a new test tube and evaporated to 
dryness. Addition of 5ml ethyl acetate/TFA (99.5/0.5, v/v) led to complete extraction of FB1 
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(recovery 99%) into the ethyl acetate/TFA phase. This extract also contained a significant 
amount of co-extracted matrix components, which was due to the high acid strength of the 
TFA used. Lower percentages of TFA led to a reduction in the amount of co-extracted matrix 
components, but the recovery for FB1 was greatly compromised.  
 
As a further setback, DON-3Glu and AFB1-N7Gua were not retained on the Oasis HLB 
cartridges, as a result the extraction recoveries for these analytes were less than 5% and 10% 
respectively. On the other hand LLE with acidified ethyl acetate (1% FAc) resulted in 
extraction recoveries of 57% and 76% for DON-3Glu and AFB1-N7Gua respectively. 
However, the extraction recoveries for DON, DOM and OTα after Oasis HLB SPE clean-up 
were 70%, 85% and 89% respectively which were higher than those obtained with the SAX 
SPE approach, 55%, 48% and 62% for DON, DOM and OTα respectively. All the other 
analytes had very satisfactory extraction recoveries (greater than 72%) with both clean-up 
approaches. Data on apparent recovery are discussed in section 3.5. 
In general, the LODs obtained with the SAX clean-up approach were 3-9 fold lower than 
those obtained with the Oasis HLB SPE cartridges. This could be attributed to a better sample 
clean-up (better elimination of matrix interferences) with the SAX approach than with the 
Oasis HLB cartridges. For these reason, extraction with acidified ethyl acetate followed by 
SAX SPE clean-up was selected as a suitable extraction and sample clean-up procedure 
 
LLE of FB1 from urine has been a challenge in the field of mycotoxin research. Less than 
10% of FB1 was extracted with the extraction solvent (ethyl acetate/FAc (99/1, v/v)). For this 
reason there was the need to perform SPE clean-up using SAX SPE cartridges with the aim of 
obtaining a satisfactory recovery for this analyte. Data from the literature revealed that prior 
to SAX SPE clean-up, complete ionization of FB1 was achieved when the pH of the sample 
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extract (in this case, sweet pepper extract) was adjusted to between 5.8 to 6 [44]. However, in 
this study, complete ionization of FB1 was achieved at pH 6.5-7, which highlights once more 
the influence of sample matrix on the ionization of FB1 [45]. The strength of the base used for 
adjusting the pH was also found to have a significant influence in the degree of ionization and 
or hydrolysis of FB1.. Hydrolysis was observed by quantifying the presence of HFB1 in the 
final extract. A strong base or alkali such as NaOH and triethylamine led to significant 
hydrolysis of FB1. A milder inorganic base such as Na2CO3 gave complete ionization of FB1 
with no hydrolytic products. After adjusting the pH to 6.5-7 it was also necessary to dilute the 
urine samples before loading the extract on the SPE cartridges. Fivefold dilution with 
methanol or isopropanol (1/5, v/v) resulted in 100% retention of the ionized FB1 on the SAX 
cartridges. Meanwhile, for a non-diluted sample, less than 30% of the ionized FB1 was 
retained on the SAX cartridges.  
 
3.3 Optimization of the LLE protocol 
 
As previously mentioned, the LLE protocol was optimized by means of an experimental 
design. The factors included (1) extraction solvent (2) varying percentages of FA (3) volume 
of extraction solvent (4) extraction time and (5) evaporation temperature. The classical 
approach to estimate the effect of control factors on the relevant response is by the use of a 
standard central composite design. However, since qualitative factors (extraction solvent) 
were included in our design, this posed a very serious restriction in the use of this design. 
Moreover, central composite designs may also have the shortcoming of needing a 
predetermined number of runs which, in some cases, is considerably higher than what is 
strictly necessary [46]. A D-optimal design with 37 runs performed in one randomized batch 
(in duplicate measurement) was well suited to be used for this optimization. In general, if a 
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factor was found to be insignificant, the least time-consuming or the cheapest level of the 
factor was considered. Conversely, if a factor was considered critical, the level of the factor 
which gave the highest response was considered in the final experimental protocol. Should 
there be conflicting outcomes, the favorable level of a factor was decided by the number of 
analytes for which the highest response was obtained. From the regression coefficient plot 
(not shown), it was observed that the quantitative parameters i.e percentage of acid, volume of 
extraction solvent and extraction time in that order had the most influence on the analyte 
response (recovery). All interaction and quadratic effects were found insignificant since the 
error bars were much larger than the regression coefficients. Ranking of the qualitative factors 
in order of significance, revealed that ethyl acetate had the most significant influence 
(positive) on the analyte response followed by methyl-ter-butyl ether and chloroform. To 
better estimate the influence of the different quantitative parameters on the analyte signal, 
response surface plots were constructed. Figure 2 shows the different response plots for β-
ZOL (as an example) for different combinations of the parameters investigated. The response 
surface plots for a majority of the other analytes were similar to that of β-ZOL. These 
response surface plots were used to select the best optimum conditions for sample 
preparation. The optimum conditions were chosen by taking into consideration data obtained 
from the regression coefficient plots and the response surface plots. The following conditions 
were chosen as optimum and subsequently used for the analysis of urine samples: extraction 
solvent ethyl acetate, percentage of acid 1%, extraction time 30mins, and extraction volume 
15 mL. All statistical analysis were performed using MODDE 9.0 software (Umetrics, 
Malmo, Sweden). 
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3.4 Optimization of the LC-MS/MS conditions 
 
Optimization of the LC separation parameters and MS detection conditions was performed 
with analytical standards spiked in pure solvent. Addition of FAc to the mobile phase did not 
only improve the analytical signal of most of the analytes, but also resulted in a more efficient 
separation of the two zearalenol isomers (α-ZOL and β-ZOL), without which both peaks 
overlapped with each other. Furthermore, the retention time of DON-3GLu was greatly 
influenced through the acidification of the mobile phases. Non acidification (pH 6) resulted in 
a retention time of 6.5 mins for DON-3GLu as opposed to 4.29 mins with an acidified mobile 
phase (pH 3). The retention time of 6.5 mins would have been preferred as it led to a better 
separation of this analyte from matrix interferences and hence a much better signal intensity 
for DON-3Glu. However, non-acidification was not considered because the signal intensity 
for most of the other analytes was greatly compromised. Thus acidification of the mobile 
phase was desirable. Adding 0.3% aliquot of FAc in the mobile phases gave optimal signal for 
most of the analytes. 
All of the analytes except α-ZOL, β-ZOL, DON-3Glu and DON were most sensitive in the 
positive electrospray ionization mode (ESI+) than in the negative electrospray ionization 
mode (ESI-). For this reason, ESI+ was chosen and used in this work.  
 
Addition of ammonium acetate has proven to be necessary to support the formation of 
[M+NH4
+
] adducts, which appear to be the most predominant ions in the spectra of DON-
3Glu, T2 and HT2. For ZEN-4Glu, a sodium adduct was the predominant precursor ion 
[M+Na
+
]. All the other analytes had protonated molecules as precursor ions (Table 1). 
Meanwhile the use of ammonium formate as an additive in the mobile phase gave a 
significantly much higher signal compared to ammonium acetate, for most of the analytes.  
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3.5 Validation results and matrix effect 
 
Insufficient method specificity most often results from co-eluting interfering (matrix) peaks 
which could eventually lead to a high false positive rate. The specificity of the method was 
evaluated by measuring the relative ion intensities of the analytes in pure solvents and in 
spiked blank samples. A tolerance limit of 20% (based on the ion ratio) was used as 
recommended in Commission Decision 2002/657/EC. Should incase the tolerance limit in an 
alleged positive sample was greater than 20%, the product ion scan of the selected peak was 
obtained and the spectra compared with those of a standard solution. In case of non-
conformity, the sample in question will be considered as false positive for this analyte. This 
situation was encountered with CIT in 70% of the samples analyzed whereby the ion ratio 
exceeded 20%. 
 
The lack of fit test for linearity resulted in p value > 0.05 for all the analytes which illustrates 
the reliability of the chosen calibration range(s) for the quantification of the different analytes 
in real samples (Table 2). In addition, the coefficient of determination (R squared) was also 
determined and was between 0.9774-0.9994 for all the different analytes. The data shown in 
Table 2 also revealed LODs within the range of 0.01-2.88 ng/mL. The method LODs were in 
most cases less than 1ng/mL except for DON, DON-3Glu, CIT and ZEN which had LODs of 
2.85 ng/mL, 2.25 ng/mL, 2.88 ng/mL and 1.24 ng/mL respectively. These four LOD values 
might seem to be a bit high, especially for biomarker studies, however, considering the 
concentration of these analytes which have been reported in urine samples from previous 
studies, the LODs reported herein were satisfactory enough to be used in this biomarker 
study.  
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The apparent recovery data evaluated at concentrations of 10 times the method LOQ for the 
different analytes were expressed as bias. The values ranged from 1-15% for all the 
compounds as shown in Table 2. The intra-day and inter-day precision values were in the 
range 5-19% and 8-29% respectively (Table 2). Because of the possible variability which 
could occur at the low concentration range of the analytes investigated, a statistical graphical 
(boxplot) test to detect or identify outliers was performed after checking for normality of the 
entire sample distribution. Outliers were excluded and the test performed again until all the 
other outliers were eliminated. The satisfactory RSD for the intra-day and inter-day 
repeatability could be attributed to the elimination of outliers from the dataset. The Cochran's 
“C” test revealed that the variation (population variance) on the different days were equal 
since the results obtained on the different days and different concentration levels were not 
significantly different.  
 
Figure 3 shows the results of matrix effect. The polar analytes DON, DON-3Glu suffered the 
most signal suppression, likewise CIT. Almost no signal suppression was observed for AFB1, 
AFM1, FB1 and OTA. For the rest of the other analytes, at least 60% of the original signal was 
recovered which was considered satisfactory.  
 
3.6 Stability study 
 
Data on the stability of mycotoxin biomarkers in human urine have not yet been reported. 
Such information could be very vital when carrying out field sampling during which urine 
samples are to be collected and stored temporary in a non-laboratory setting (room 
temperature and or refrigeration) and later transported to the laboratory for long term storage 
prior to analysis. Data (Figure 4a) obtained from the short term stability studies (3hrs and 6hrs 
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at 4°C and 25°C) revealed an almost insignificant degradation (<10%) of the different 
analytes at the different time-temperature combinations, except for CIT, for which less than 
80% of the spiked analyte concentration was recovered after 6hrs at 25°C. Though no 
significant differences were found between samples stored at 4°C and 25°C, it is advisable to 
store samples at 4°C or in dry ice when carrying sampling on the field. The additional short 
term stability studies performed at 4°C and 25°C for 1 day, 3 days and 5 days resulted in a 
very interesting outcome. From the results (Figure 4b), it could be seen that all analytes were 
stable after day 1 irrespective of the storage temperature. Meanwhile for day 3 and day 5, 
significant losses were recorded. At least 50% of the initially spiked analyte concentrations 
was lost for samples kept at 25°C for 5 days. HT2, AFM1, AFB1, DOM and T2 toxins were 
the most degraded. Less than 30% of the initial concentration of T2 toxin was recovered after 
day 5 irrespective of the storage temperature. The non-polar analytes of the group (ZEN, β-
ZOL, α-ZOL, OTA) were the least degraded irrespective of the time-temperature 
combinations when compared to the polar analytes such as DON, DON-3Glu, and DOM. For 
the long term stability test, an almost insignificant degradation (<5%) of the different analytes 
was observed after 2 months of storage at -20°C (data not shown). 
 
3.7 Results of pilot study 
 
The Crea results obtained with the in-house spectrophotometric method was in good 
agreement (inaccuracy 0-14%) with those obtained from two external accredited laboratories 
(data not shown). Quantitative results obtained from the biomarker analysis were expressed in 
mg Crea, thereby correcting for any possible dilution effect. 
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Analysis of all 40 urine samples was carried out without β-glucuronidase digestion (direct 
method of analysis). Table 3 shows the different biomarkers and their corresponding 
concentrations in the positive urine samples. In total 9 samples were found positive with one 
or more of the following analytes; DON, OTA, OTα, 4-OH OTA, ZEN, CIT and β-ZOL. 
One-eighth (5/40) of the samples were contaminated with DON (3.7-67 ng mg
-1
 Crea). In 
samples with quantifying levels of DON, DON-3Glu was not detected. However, not been 
able to detect DON-3Glu in subjects 5 and 9 with relatively high DON concentrations of 47 
and 67 ng/mL is intriguing and warrants further investigation with a much larger population 
size 
 
4-OH OTA (<LOQ) was detected in one sample, co-occurring with only OTA (0.2 ng mg
-1
 
Crea). High levels of OTα (up to 4.4 ng mg-1 Crea) were detected in three samples co-
occurring with very low levels of OTA (up to 0.3 ng mg
-1
 Crea). Figure 5 shows the 
chromatogram of positive sample 1 with detectable levels of DON, OTA and OTα. The 
concentration of  OTα was always higher than those of OTA, which has also been reported by 
Munoz et al. [13]. These findings further confirm the fact that OTα is the principal metabolite 
of OTA detoxification in humans and not 4-OH OTA.  
 
ZEN was detected in 10% (4/40) of the samples analyzed. A full MS scan performed for 
ZEN-4Glu did not show any detectable levels of this analyte which has been highlighted to be 
a possible biomarker for ZEN exposure [19]. In comparison to the findings of Massart et al. 
[18], who reported occurrence of α-ZOL and ZEN in the serum of female subjects affected by 
precocious puberty in the United States, we detected three samples co-contamination of β-
ZOL (3.3-20 ng mg
-1
 Crea) and ZEN (<LOQ-10.8 ng mg
-1
 Crea). α-ZOL was not detected in 
any of the 40 samples. The ratio of ZEN/β-ZOL varied for all the three samples. Figure 6 
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shows the chromatogram of sample 6 with detectable levels of β-ZOL and ZEN. CIT was 
detected in one sample at 4.5 ng mg
-1
 Crea. All the identification criteria for peak 
confirmation were taken into account for the final confirmation of results. 
 
4. Conclusion and recommendation 
 
A sensitive LC-MS/MS method for the detection of mycotoxins and their metabolites (total 18 
analytes) in human urine was successfully developed. LLE with acidified (1% FAc) ethyl 
acetate followed by SAX SPE clean-up showed very satisfactory apparent recovery values for 
all the analytes. Hence LLE followed by SAX SPE clean-up could be considered as a cheaper 
alternative for sample extraction and clean-up as compared to the use of immunoaffinity 
columns which had been widely reported by other authors. Direct determination of the 
glucuronides DON-3Glu and ZEN-4Glc was possible without enzyme digestion.  
 
Occurrence of one or more of the following analytes DON, OTA and its metabolites, ZEN 
and its metabolites and CIT were detected in nine of the 40 samples analyzed. These results 
highlight the need to perform a more rigorous exposure assessment with different age groups 
within the Belgian population, especially children.  
 
Most of the analytes were stable for up to 1 day at both refrigeration conditions (4°C) and at 
room temperature (25°C). Prolong storage for 3 days and 5 days resulted in significant 
degradation of these analytes, with T2 been the most affected. Thus, cold storage of urine 
samples during field sampling is strongly encouraged and all samples should be frozen within 
24 hrs after collection.  
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Tables and Figures 1 
Table 1: MS/MS parameters of the selected analytes 2 
Analyte 
Retention 
time (min) Precursor ion (m/z) 
Cone 
Voltage 
(V) 
Product ions 
(m/z) 
Collision 
energy (eV) 
DON-Glu 4.26 490 M+NH4+ 15 
297* 
243 
10 
15 
DON 4.50 297.10 M+H+ 18 
249.20* 
203.10 
12  
16 
DOM 5.73 281.10 M+H+ 18 
109.20* 
233.20 
17 
10 
AFB1-
N7Gua 6.34 481 M+H+ 22 
152* 
329 
28 
18 
AFM1 7.25 329 M+H
+ 34 
273.10* 
229.10 
25 
40 
OT 7.68 257 M+H+ 12 
239* 
221 
15 
25 
AFB1 8.73 313 M+H
+ 30 
285.10* 
241.10 
20 
35 
CIT 9.13 251.50 M+H+ 25 
90* 
233.40 
40 
20 
HFB1 9.68 405.90 M+H
+ 32 
370* 
388 
20 
20 
HT-2 11.06 442.10 M+NH4+ 16 
263.10* 
215.20 
15 
15 
ZEN-14Glu 10.22 517 M+Na+] 35 
340.80* 
323.0 
25 
25 
-ZOL 11.39 321,10 M+H+ 15 
285.20* 
303.20 
10 
13 
FB1 12.39 722,3 M+H
+ 45 
334.20* 
352.20 
35 
35 
T-2 12.75 484.20 M+NH4+ 18 
305.20* 
215.10 
15 
19 
-ZOL 13.87 321,10 M+H+ 10 
285.20* 
303.20 
10 
13 
ZEN 13.32 319,10 M+H+ 15 
301.10* 
283.20 
10 
15 
4-OH OTA 14.47 419 M+H+ 20 
255* 
271 
15 
10 
OTA 14.63 404 M+H+ 20 
239* 
358 
25 
10 
*Most abundant product ion 3 
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Analytes Concentration 
range (ng/mL) 
Lack of fit 
(p-value) 
R2 Apparent 
recovery 
(bias, %) 
LOD 
(ng/mL) 
LOQ 
(ng/mL) 
a
RSDr 
(%) 
a
RSDR 
(%) 
DON-3Glu 
5-50 0.095 0.9882 11 2.25 4.5 19 29 
DON 
5-50 0.062 0.9892 8 2.85 5.7 16 19 
DOM 
5-100 0.412 0.9870 11 0.65 1.30 7 15 
AFB1-N7Gua 
1-50 0.150 0.9923 6 0.85 1.70 9 12 
AFM1 
0.05-10 0.123 0.9980 5 0.01 0.02 8 8 
OT 
0.1-20 0.992 0.9991 4 0.03 0.06 11 13 
AFB1 
2-20 0.080 0.9774 2 0.83 1.66 11 15 
CIT 
5-50 0.327 0.9936 12 2.88 5.76 13 27 
HFB1 
1-50 0.236 0.9994 3 0.51 1.02 10 18 
HT-2 
1-20 0.096 0.9976 7 0.42 0.84 7 21 
-ZOL 
5-20 0.178 0.9904 6 1.1 2.2 8 11 
FB1 
0.2-20 0.215 0.9946 8 0.05 0.1 5 11 
T-2 
0.2-20 0.369 0.9992 5 0.05 0.1 9 11 
-ZOL 
2-20 0.053 0.9845 9 0.61 1.22 8 10 
ZEN 
5-50 0.625 0.9933 15 1.24 2.48 8 9 
ZEN-4Glu 
1-50 0.123 0.9985 14 3.65 7.3 13 23 
4-OH OTA 
1-20 0.263 0.9875 12 0.12 0.24 14 22 
OTA 
0.1-10 0.479 0.9991 1 0.03 0.06 5 15 
Table 2: Linearity, apparent recovery, LOD, LOQ and repeatability of the different 
R2: coefficient of determination. RSD: relative standard deviation. RSDr: intra-day precision. . RSDR: inter-day precision. 
a
RSD: data were obtained from 10 ng/mL 
spiked concentration levels 
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Table 3. Mycotoxin contamination levels for the different urine samples 4 
 5 
 Analytes concentration (ng mg
-1
 creatinine) 
 
Un-corrected analyte concentration (ng/mL) 
Sample(s)  
OTA OTα 
4-OH 
OTA 
ZEN β-ZOL DON CIT OTA OTα 
4-OH 
OTA 
ZEN β-ZOL DON CIT 
1 0.3 2.5 nd nd nd 15.2 nd 0.61 5.1 nd nd nd 31 nd 
2 0.04 6 nd <LOQ 3.3 15.2 nd 0.1 15 nd <LOQ 8.3 38.1 nd 
3 nd nd nd 3.2 12 nd nd nd nd nd 4.3 16.1 nd nd 
4 0.1 4.4 nd nd 2,5 3.7 nd 0.16 7.0 nd nd 4 5.9 nd 
5 nd nd nd nd nd 47 nd nd nd nd nd nd 62.5 nd 
6 nd nd nd 10.8 20 nd nd nd nd nd 12.6 24.8 nd nd 
7 0.2 nd <LOQ nd nd nd nd 0.6 nd <LOQ nd nd nd nd 
8 nd nd nd nd nd nd 4.5 nd nd nd nd nd nd 6.8 
9 nd nd nd <LOQ nd 67 nd nd nd nd <LOQ nd 68.3 nd 
 6 
  7 
 8 
 9 
 10 
 11 
nd: not detected. <LOQ: less than limit of detection 
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Figure 1 13 
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Figure 2 17 
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 21 
 22 
Figure 3 23 
The error bars represent the standard deviations obtained from the five different individual samples. Calibration range, same as those used to 24 
determine the method linearity (see Table 2). 25 
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 34 
Figure 4a 35 
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 42 
Figure 4b 43 
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Figure 5 
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Figure 6 
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Figure captions 
Figure 1: Schematic overview of the sample preparation protocol 
Figure 2: Response surface plot for β-ZOL 
Figure 3: Matrix effect for the different analytes 
Figure 4a: Short term stability study at 4°C and 25°C for 3 hrs and 6 hrs storage time 
Figure 4b: Short term stability study at 4°C and 25°C for 3 days and 5 days storage period 
Figure 5: Chromatogram of sample 1 showing co-occurrence of DON, OTA and OTα 
Figure 6: Chromatogram of sample 6 showing co-occurrence of ZEN and β-ZOL 
 
